FdaApplication
NDA 022445
Identifiers
- fda_app_no: NDA022445
Properties
| Property | Value |
|---|---|
| applicant_name | HERON THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2016-08-09 |
Revenue by product
SUSTOL
| Period | Revenue |
|---|---|
| Q2 2026 | $0.5M |
| Q1 2026 | $0.5M |
| Q4 2025 | $1.3M |
| Q3 2025 | $1.9M |
| Q2 2025 | $2.4M |
| Q1 2025 | $2.9M |
| Q4 2024 | $3.5M |
| Q3 2024 | $2.8M |
| Q2 2024 | $4.2M |
| Q1 2024 | $3.6M |
| Q4 2023 | $3.8M |
| Q3 2023 | $3.4M |
| Q2 2023 | $2.8M |
| Q1 2023 | $3.0M |
| Q4 2022 | $3.1M |
| Q3 2022 | $2.7M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| SUSTOL | GRANISETRON | 10MG/0.4ML (10MG/0.4ML) | INJECTABLE;SUBCUTANEOUS |
1 product